Segall Bryant & Hamill LLC Sells 1,879 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Segall Bryant & Hamill LLC decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 1.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 139,743 shares of the biotechnology company’s stock after selling 1,879 shares during the period. Segall Bryant & Hamill LLC’s holdings in Blueprint Medicines were worth $12,188,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Torray Investment Partners LLC boosted its position in shares of Blueprint Medicines by 1.1% during the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock valued at $1,439,000 after purchasing an additional 186 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after buying an additional 265 shares in the last quarter. Hillsdale Investment Management Inc. boosted its holdings in shares of Blueprint Medicines by 0.6% during the 4th quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company’s stock worth $4,433,000 after buying an additional 310 shares in the last quarter. Quarry LP acquired a new stake in shares of Blueprint Medicines during the 3rd quarter worth approximately $32,000. Finally, Van ECK Associates Corp lifted its position in shares of Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 363 shares during the period.

Analyst Ratings Changes

Several research firms have weighed in on BPMC. Morgan Stanley assumed coverage on shares of Blueprint Medicines in a research note on Thursday, March 20th. They issued an “equal weight” rating and a $100.00 price target for the company. Piper Sandler boosted their target price on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Wolfe Research started coverage on Blueprint Medicines in a report on Tuesday, March 18th. They issued an “outperform” rating on the stock. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. Finally, StockNews.com lowered Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $124.95.

Blueprint Medicines Stock Performance

Shares of Blueprint Medicines stock opened at $93.08 on Wednesday. The business’s fifty day simple moving average is $99.12 and its 200 day simple moving average is $93.97. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90. The firm has a market capitalization of $5.95 billion, a P/E ratio of -86.18 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insider Activity

In other news, Director Jeffrey W. Albers sold 15,161 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the transaction, the director now owns 152,396 shares of the company’s stock, valued at $16,691,933.88. This represents a 9.05 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the sale, the chief executive officer now directly owns 149,378 shares of the company’s stock, valued at approximately $16,467,430.72. This trade represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,334 shares of company stock valued at $3,103,512 in the last three months. Company insiders own 4.21% of the company’s stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.